TP53 and Miyoshi myopathy: Despite considerable progress in the treatment of MM, particularly with the emergence of immune-based therapies, it remains unclear how to overcome drug resistance, especially in high-risk patients with TP53 abnormalities, including del17p and/or TP53 mutations.2, 3, 4 Deregulated oncogene expression can alter replication timing and transcriptional programs, resulting in increased replication stress (RS), generally referred to as oncogene-induced RS.5